Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

in Our Study we Compare Results of Two Oncoplastic Breast Surgery (Short Scar Reduction Mammoplasty and Wise Pattern Reduction Mammoplasty) as Surgical Treatment of Breast Cancer

NCT06901180 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-04-01
Last updated
2025-03-28

Condition(s) studied

Evaluation of Short Scar Periareolar Inferior Pedicle Reduction Mammoplasty in Oncoplastic Breast Surgery

Investigational drug(s) / intervention(s)

short scar periareolar inferior pedicle reduction mammoplasty

short scar periareolar inferior pedicle reduction mammoplasty: reduction mammoplasty that minimizes scar with better cosmetic outcomes

Study summary

in our study we compare results of two oncoplastic breast surgery (short scar reduction mammoplasty and wise pattern reduction mammoplasty) as surgical treatment of breast cancer

Eligibility

Sex
FEMALE
Min age
25 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Female patients with ages ranging from 25 to 75 years. 2. Patients with operable breast cancer (Stage I, II and IIIa). 3. Patients with moderate to large /ptotic breasts. Exclusion Criteria: 1. Patients with a contraindication to breast conservative surgery: 1. Multi-centric disease that can't be incorporated by local excision through a single incision that achieves adequate safety margin and satisfactory cosmetic results. 2. inflammatory carcinoma. 3. Contraindications to postoperative radiation e.g. pregnancy, pre-existing lung disease with reduced diffusing capacity and pulmonary TB. 4. diffuse suspicious malignant micro-calcification on mammography. 5. inability to attain negative surgical margins. 6. cardiomyopathy 7. connective tissue disorders with significant vasculitis. 2. Previous chest wall or breast radiation. 3. Patients' refusal participation.

Primary outcome measure(s)

  • oncological outcomes — 1 year
    detect incidence of local recurrence of malignancy
  • post operative complications — 1 month
    surgical complications
  • cosmetic outcomes — 1 year
    patients' satisfaction with their breast

Trial sites (1)

FacilityCityRegionStatus
Sohag University Sohag Sohag Governorate
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06901180 on ClinicalTrials.gov ↗ ← All trials in Egypt